UCB's Global Corporate Website

UCB at the 1st International Societies for Investigative Dermatology (ISID) Meeting

Posted by
Eimear O'Brien, Global Communications & Company Reputation

The Inaugural Meeting of the International Societies for Investigative Dermatology (ISID) is taking place this week in Tokyo, Japan, 10-13th May 2023.  ISID is an organization focused on the advancement of investigative dermatology and cutaneous biology. As a Company committed to advancing patient care in chronic dermatological conditions such as psoriasis and hidradenitis suppurativa (HS), UCB is proud to participate in this international meeting.

ISID 2023 offers an exciting four-day program of outstanding cutting-edge data and science. We look forward to joining the dermatology community over the next few days to discuss the latest research. Healthcare professionals attending ISID 2023 will have the opportunity to join two UCB symposia focused on HS and psoriasis:

  • Understanding Hidradenitis Suppurativa: an educational symposium, Thursday, May 11th, 12:05 - 13:05 JST 
  • Spotlight on Psoriasis: new perspectives on therapy and pathology, Saturday, May 13th, 12:05-13:05 JST.

In addition, UCB is proud and honoured to have two scientific abstracts accepted for presentation at this inaugural meeting, with one focused on hidradenitis suppurativa accepted as an oral presentation, and one on psoriasis accepted as a poster presentation.

At UCB, we understand that significant unmet needs remain in HS and psoriasis. We are committed to collaboration with the community to help advance science aimed at elevating standards of care. Meetings such as ISID 2023 provide a welcome forum to engage, connect and accelerate progress aligned to our common purpose.

If you are a healthcare professional attending #ISID2023, we look forward to meeting with you in Tokyo.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.


Enter the characters shown in the image.